We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NYU Medical Center Partners with Rosetta Genomics to Develop Diagnostic Tools for Lung and Mesothelioma Cancers
News

NYU Medical Center Partners with Rosetta Genomics to Develop Diagnostic Tools for Lung and Mesothelioma Cancers

NYU Medical Center Partners with Rosetta Genomics to Develop Diagnostic Tools for Lung and Mesothelioma Cancers
News

NYU Medical Center Partners with Rosetta Genomics to Develop Diagnostic Tools for Lung and Mesothelioma Cancers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NYU Medical Center Partners with Rosetta Genomics to Develop Diagnostic Tools for Lung and Mesothelioma Cancers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics, Ltd. has announced that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung, and Mesothelioma cancers.

The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibers. The test will utilize Rosetta Genomics' proprietary protocol to extract microRNAs from a simple blood draw.

"A test that will be able to detect cancer at an early stage using a simple blood draw will have far reaching implications on the fight against cancer," noted Dr. Harvey Pass, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center.

"MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers, and I believe that NYU Medical Center's vast experience with lung cancer and Mesothelioma, coupled with Rosetta Genomics' expertise in the microRNA field, will allow us to successfully advance this much needed test forward."

Advertisement